Genmab A (GMAB) Total Non-Current Liabilities (2018 - 2026)

Genmab A (GMAB) has reported Total Non-Current Liabilities for 9 consecutive years, with $5.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 916.51% year-over-year to $5.4 billion; the trailing twelve-month figure through Jun 2026 stood at $5.4 billion (up 916.51% YoY), and the FY2025 full-year result was $5.6 billion, up 950.47% from the prior year.
• Total Non-Current Liabilities declined to $5.4 billion in Q2 2026 per GMAB's latest filing, from $5.5 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $5.6 billion in Q4 2025 and bottomed at $44.8 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $1.1 billion across 5 years, with a median of $146.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities retreated 19.59% in 2022, then soared 1481.11% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $44.8 million in 2022, then soared by 150.63% to $112.3 million in 2023, then surged by 215.44% to $354.1 million in 2024, then soared by 1481.11% to $5.6 billion in 2025, then decreased by 3.23% to $5.4 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $5.4 billion, $5.5 billion, and $5.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.